What Genenta Science does

Genenta Science S.p.A. (Nasdaq: GNTA), headquartered in Milan and founded in 2014, is undergoing a strategic transformation from a clinical-stage immuno-oncology biotech into a Nasdaq-listed industrial consolidator rebranding as Saentra Forge. Its original biotechnology platform, Temferon, is a first-in-class autologous cell and gene therapy using gene-modified hematopoietic stem and progenitor cells (HSPCs) to express interferon-alpha locally within the solid tumor microenvironment via Tie2-expressing monocytes, with dual transcriptional and post-transcriptional regulation; the platform also underpins a clinically validated LVV Plasmid DNA technology originally developed by co-founder Professor Luigi Naldini. Following a January 2026 strategic pivot, the company is consolidating Italian companies operating in sectors protected under Italy's Golden Power framework, completing acquisitions of ATC (a NATO-qualified tactical firearms manufacturer) in January 2026 and a 51% controlling stake in Sòphia High Tech (an EN9100 and ESA-certified aerospace and defense additive-manufacturing specialist) in April 2026, while engaging DC Advisory to externalize the original biotech assets through partnerships or licensing. The group generates revenue primarily through Sòphia's hardware sales into European aerospace prime contractors and ESA programs, supplemented by ATC's institutional defense procurement and government channel sales, with a stated target to roughly double Sòphia's revenue base and headcount by 2027.

Name

Genenta Science

Legal name

Genenta Science S.p.A.

Website

http://genenta.com/

Company type

Public

Founded year

2014

Operating status

Operating

Headcount range

11–50 employees

Short description

Genenta Science (Nasdaq: GNTA), rebranding as Saentra Forge, is a Milan-based industrial consolidator acquiring Italian companies in defense, aerospace, and national security sectors protected under Italy's Golden Power framework, with operating subsidiaries in tactical firearms (ATC) and aerospace additive manufacturing (Sòphia High Tech), while externalizing its original Temferon gene-therapy biotech platform.

Ownership category

akta.pro rank

Product category

Biotechnology and Defense Manufacturing

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL)

akta.pro secondary industries

Oncology Gene Therapies (incl. oncolytic vectors & gene-modified approaches) (HLAAACAF), Neurology/CNS Gene Therapies (HLAAACAH)

Keywords

• Cell gene therapy
• Immuno-oncology platform
• Aerospace defense manufacturing
• Industrial consolidator
• Precision tactical systems

Headquarters

HQ city

Milano

HQ country

Italy

HQ region

Europe

Offices5 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Infrastructure

Revenue model

1. Biotechnology Clinical Development: Pre-revenue clinical-stage biotech company developing Temferon for solid tumors. Revenue generation through potential partnerships, licensing, or eventual product commercialization. Currently exploring external partnerships to monetize biotech assets.
2. Defense and Aerospace Manufacturing: Through acquired entities (ATC, Sòphia High Tech), the company generates revenue from manufacturing and selling precision tactical systems, aerospace components, and defense products to institutional, defense, and professional markets.
3. Industrial Consolidation Services: Acquiring majority stakes in profitable private companies at private market valuations, integrating them within a Nasdaq-listed industrial group to build value through operational expertise and long-term development.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels6 records

Core offering

Genenta Science develops Temferon, a first-in-class autologous cell and gene therapy platform using gene-modified hematopoietic stem cells to deliver interferon-alpha directly to solid tumors. Through acquired subsidiaries ATC (precision tactical firearms) and Sòphia High Tech (aerospace and defense components), the company operates as a strategic industrial consolidator targeting Italy's Golden Power-protected sectors.

Product overview

Genenta Science, evolving into Saentra Forge, operates as a strategic industrial consolidator focused on defense, aerospace, and national security sectors. The company's portfolio includes three main products: (1) Temferon™ - a first-in-class autologous cell and gene therapy platform for solid tumor treatment using gene-modified hematopoietic stem cells; (2) ATC - a high-precision manufacturer of tactical rifles and special-forces weapon systems; and (3) Sòphia High Tech - an aerospace and defense engineering company specializing in precision mechanical components and additive manufacturing for space programs. The company is transitioning from its original biotechnology focus toward becoming an industrial aggregator for strategic technologies protected under Italy's Golden Power framework.

Differentiator

Problem solved

Functional benefit

Brands

• Temferon™: First-in-class cell therapy platform for targeted interferon-alpha delivery using gene-modified hematopoietic stem cells for treatment of solid tumors including glioblastoma and renal cell carcinoma.
• ATC
• Sòphia High Tech

Products and services

• Temferon First-in-class, one-time autologous cell and gene therapy using gene-modified hematopoietic stem cells (HSPCs) to deliver interferon-alpha (IFN-α) directly to solid tumors. The therapy reprograms the tumor microenvironment by exploiting Tie2-expressing monocytes as precision delivery vehicles, enabling localized and sustained therapeutic activity while minimizing systemic toxicity. Currently in clinical trials for glioblastoma multiforme and metastatic renal cell carcinoma.
• ATC (Armi Tattiche Custom) Tactical Firearms Italian high-precision manufacturer of tactical rifles, chassis systems, optics mounts, bipods, and related accessories for special forces and competition-grade sporting firearms. Operates with vertical integration from CAD/CAM design through precision CNC machining to finishing, assembly, and final inspection. Holds NATO qualifications and Italian Ministry of Defense authorization.
• Sòphia High Tech Aerospace and Defense Components Italian aerospace and defense engineering and manufacturing company producing critical mechanical components for space and defense systems. Capabilities include advanced manufacturing techniques including metal 3D printing (Selective Laser Melting), CNC precision machining, and exotic materials processing (titanium, Inconel, tungsten, specialized copper alloys). Certified to EN9100 aerospace standard and ECSS-Q-ST-70-80C for ESA additive manufacturing.

Quantifiable outcome

• 29% two-year survival rate vs ~14% in historical uMGMT standard-of-care cohorts
• +4 more outcomes

Named customers9 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Nine partnerships are on record, tiered core and minor.

• Sòphia High Tech S.r.l.coreStrategic or Co-development Partner · 27 March 2026Genenta (evolving into Saentra Forge) signed binding offer to acquire controlling stake in Sòphia High Tech, an Italian aerospace and defense engineering and manufacturing company. €6 million initial investment for 19.9% stake with path to 51% majority ownership. Sòphia builds critical mechanical components for space and defense systems including precision parts for rockets, satellites, and aircraft. The transaction aims to scale production and maintain Italy's national security technological assets.
• ATC (Armi Tattiche Custom)coreStrategic or Co-development Partner · 27 January 2026Initial investment of up to €5.1 million in ATC, a NATO-qualified manufacturer of tactical rifles and special-forces weapon systems. Genenta entered a binding agreement to fund ATC with goal of acquiring controlling position upon achievement of performance milestones. ATC is a high-precision manufacturer with UAMA and SeRMI export-control licenses and Italian Ministry of Defense authorization.
• DC AdvisorycoreImplementation/ SI/ Consulting Partner · 27 January 2026Genenta hired DC Advisory to monetize its biotech assets through partnerships while positioning as a strategic consolidator. DC Advisory is engaged to explore strategic options for the original biotechnology platform derived from Professor Luigi Naldini's research.
• AnemocytecoreStrategic or Co-development Partner · 24 October 2025Expanded strategic collaboration focused on off-the-shelf lentiviral vector Plasmid DNA technology for advanced therapy development. Building on existing successful partnership in plasmid DNA manufacturing, Anemocyte gains access to Genenta's clinically validated LVV Plasmid DNA technology platform developed from research by co-founder Professor Luigi Naldini. The collaboration aims to offer reliable and scalable materials from R&D to GMP grade to Anemocyte's clients across the life sciences industry.
• European Space Agency (ESA)coreOthersSòphia High Tech is one of the few companies in Europe qualified to 3D-print flight-ready space hardware to ESA and NASA standards, certified to ECSS-Q-ST-70-80C specification for additive manufacturing.
• AVIO S.p.A.coreOthersSòphia serves AVIO for rocket propulsion components and the Multi-Purpose Green Engine (MPGE) program focused on regenerative combustion chambers realized entirely through additive manufacturing.
• Thales Alenia SpacecoreOthersSòphia collaborates with Thales Alenia Space on the ZIRÈ satellite scientific payload for low-energy gamma particle detection, developed in collaboration with Gran Sasso Science Institute, INFN.
• Gran Sasso Science Institute / INFNminorStrategic or Co-development PartnerAcademic collaboration on ZIRÈ satellite scientific payload for low-energy gamma particle detection with Domenico Borrelli (Sòphia CTO) leading technical execution.
• Avio S.p.A.coreOthersSòphia developing Crystal Eye Cherenkov telescope, a scientific instrument for gamma particle detection, for Avio S.p.a.

Scale indicators14 records

Recent moves9 records

Expansion highlights6 records

Direct peers

• bluebird bio: Clinical-stage gene and cell therapy company developing autologous gene-modified cell therapies for severe genetic diseases and oncology. Highly comparable to Genenta on autologous gene-modified cell therapy platform technology and clinical-stage biotech risk profile.
• Fiocchi Munizioni: Italian manufacturer of ammunition and tactical products serving defense, law enforcement, and sporting markets. Comparable as a defensive/sporting firearms industrial peer — Paolo Salvato (ATC board member) was previously CEO of Fiocchi, creating direct ecosystem overlap.

Broad incumbents

• CRISPR Therapeutics: Clinical-stage gene editing company developing CRISPR/Cas9-based therapies across hemoglobinopathies, oncology, and regenerative medicine. Comparable as a Nasdaq-listed gene therapy platform with multi-indication pipeline strategy.
• Intellia Therapeutics: Clinical-stage gene editing company developing in vivo and ex vivo CRISPR-based therapies. Comparable on gene therapy platform, oncology applications, and Nasdaq-listed clinical-stage biotech profile.
• Cobra Biologics (Charles River Laboratories): CDMO providing viral vector and plasmid DNA manufacturing services for gene and cell therapy developers. Comparable as a viral vector/plasmid DNA manufacturing platform serving the same advanced therapy ecosystem as Genenta's LVV Plasmid DNA platform.

Emerging players

• Editas Medicine: Clinical-stage gene editing company developing CRISPR-based and engineered cell therapies for serious diseases. Comparable on gene-modified cell therapy approach and Nasdaq-listed clinical-stage biotech profile.
• Beam Therapeutics: Clinical-stage precision genetic medicine company developing base editing therapies. Comparable as a Nasdaq-listed biotech using advanced gene engineering platforms with oncology and rare disease applications.
• Verve Therapeutics: Clinical-stage gene editing company developing in vivo therapies for cardiovascular disease. Comparable on gene therapy platform architecture and Nasdaq-listed clinical-stage profile, though focused on different therapeutic area.
• SQZ Biotechnologies: Clinical-stage cell therapy company using Cell Squeeze technology to engineer immune cells. Comparable on cell engineering approach; board member Armon Sharei founded SQZ, providing direct ecosystem linkage.

Others

• Anemocyte: Strategic partner providing cell and gene therapy manufacturing services including LVV plasmid DNA. Highly relevant ecosystem participant given Genenta's expanded plasmid DNA collaboration.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/genenta

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Subsidiaries3 records

Funding overview

Funding rounds6 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Genenta Science